Therapeutic Advances in Endocrinology and Metabolism This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Effect of zoledronic acid on serum calcium in Paget's disease patients after educational strategies to improve calcium and vitamin D supplementation
Conclusions: These results suggest that, with optimization of calcium and vitamin D supplementation by physician and patient education, hypocalcemia is an infrequent occurrence following zoledronic acid infusion. (Source: Therapeutic Advances in Endocrinology and Metabolism)
Source: Therapeutic Advances in Endocrinology and Metabolism - August 4, 2015 Category: Endocrinology Authors: Tucci, J. R., Bone, H. G., Su, G., Tan, M., Ozturk, Z. E., Aftring, P. Tags: Original Research Source Type: research

The effects of intermittent vitamin D3 supplementation on muscle strength and metabolic parameters in postmenopausal women with type 2 diabetes: a randomized controlled study
Conclusions: Vitamin D3 supplementation in doses equivalent to 942 IU/day improved isometric handgrip strength, but had no effect on glycaemic control in postmenopausal women with longstanding type 2 diabetes. (Source: Therapeutic Advances in Endocrinology and Metabolism)
Source: Therapeutic Advances in Endocrinology and Metabolism - August 4, 2015 Category: Endocrinology Authors: Cavalcante, R., Maia, J., Mesquita, P., Henrique, R., Griz, L., Bandeira, M. P., Bandeira, F. Tags: Original Research Source Type: research

Patient preference and tolerability of a DPP-4 inhibitor versus a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study
Conclusions: In this pilot study, although both vildagliptin and liraglutide therapies were preferred similarly by the patients and showed effective control of glycemia over 12 weeks, vildagliptin was associated with fewer adverse events and was preferred more by elderly patients. (Source: Therapeutic Advances in Endocrinology and Metabolism)
Source: Therapeutic Advances in Endocrinology and Metabolism - August 4, 2015 Category: Endocrinology Authors: Ludemann, J., Dutting, E. D., Dworak, M. Tags: Original Research Source Type: research

Erratum to GLP-1 receptor agonists: a review of head-to-head clinical studies
This article was published in Therapeutic Advances in Endocrinology and Metabolism 2015, volume 6(1) 19–28, DOI: 10.1177/2042018814559725. (Source: Therapeutic Advances in Endocrinology and Metabolism)
Source: Therapeutic Advances in Endocrinology and Metabolism - June 3, 2015 Category: Endocrinology Tags: Erratum Source Type: research

Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
Glucagon-like polypeptide (GLP-1) receptor agonist treatment has multiple effects on glucose metabolism, supports the β cell, and promotes weight loss. There are now five GLP-1 agonists in clinical use with more in development. GLP-1 treatment typically can induce a lowering of hemoglobin A1c (HbA1c) of 0.5–1.5% over time with weight loss of 2–5%. In some individuals, a progressive loss of weight occurs. There is evidence that GLP-1 therapy opposes the loss of β cells which is a feature of type 2 diabetes. The chief downside of GLP-1 treatment is the gastrointestinal motility disturbance which is one ...
Source: Therapeutic Advances in Endocrinology and Metabolism - June 3, 2015 Category: Endocrinology Authors: Tella, S. H., Rendell, M. S. Tags: Reviews Source Type: research

The role of adipokines in gestational diabetes mellitus
Gestational diabetes mellitus (GDM) is a complication of pregnancy that is characterized by impaired glucose tolerance with onset or first recognition during pregnancy. The reported prevalence of GDM varies between 0.6% and 20% of pregnancies depending on screening method, gestational age and the population studied. GDM is characterized by pancreatic β-cell function that is insufficient to meet the body’s insulin needs. Available evidence suggests that β-cell defects in GDM result from the same spectrum of causes that underline hyperglycemia in general, including autoimmune disease, monogenic causes and ins...
Source: Therapeutic Advances in Endocrinology and Metabolism - June 3, 2015 Category: Endocrinology Authors: Al-Badri, M. R., Zantout, M. S., Azar, S. T. Tags: Reviews Source Type: research

Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes
Dapagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor approved as a treatment for type 2 diabetes mellitus (T2DM) in the United States, the European Union and other countries. Dapagliflozin increases renal glucose excretion in an insulin-independent manner, and its mechanism of action is complementary to those of other antidiabetes medications. When used as monotherapy or in combination with other oral antidiabetes medications or insulin, dapagliflozin improves glycemic measures in patients with T2DM. Dapagliflozin treatment is also associated with weight reduction and a decrease in blood pressure, ...
Source: Therapeutic Advances in Endocrinology and Metabolism - June 3, 2015 Category: Endocrinology Authors: Hinnen, D. Tags: Reviews Source Type: research

Evaluation of pulmonary function changes in children with type 1 diabetes mellitus in Upper Egypt
Conclusions: T1DM in children leads to impairment of lung functions and this impairment increases with poor glycemic control. (Source: Therapeutic Advances in Endocrinology and Metabolism)
Source: Therapeutic Advances in Endocrinology and Metabolism - June 3, 2015 Category: Endocrinology Authors: Mohamad, I. L., Saad, K., Abdel-Azeem, A., Mohamed, S. A. A., Othman, H. A. K., Abdel Baseer, K. A., Thabet, A. F., El-Houfey, A. A. Tags: Original Research Source Type: research